This standard of practice document briefly outlines the current approach to the diagnosis
and management of hypertrophic cardiomyopathy (HCM). The supporting levels of evidence
are reported in both the American Heart Association HCM guidelines [
[1]
] and the European Society of Cardiology HCM guidelines [
- Gersh B.J.
- Maron B.J.
- Bonow R.O.
- Dearani J.A.
- Fifer M.A.
- Link M.S.
- et al.
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:
executive summary: a report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines.
Circulation. 2011; 124: 2761-2796
[2]
]. There is also a detailed recent review of HCM for further reference [
- Elliott P.M.
- Anastasakis A.
- Borger M.A.
- Borggrefe M.
- Cecchi F.
- Charron P.
- et al.
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the
Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the
European Society of Cardiology (ESC).
Eur Heart J. 2014; 35: 2733-2779
[3]
]. Since the last CSANZ HCM guidelines in 2011, the main changes relate to emerging
sudden death risk factors such as the amount of myocardial fibrosis, the development
of an HCM Risk Score, and more careful consideration of cascade genetic testing in
asymptomatic relatives without an HCM phenotype.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart, Lung and CirculationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation. 2011; 124: 2761-2796
- 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).Eur Heart J. 2014; 35: 2733-2779
- Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.J Am Coll Cardiol. 2014; 64: 83-99
- New perspectives on the prevalence of hypertrophic cardiomyopathy.J Am Coll Cardiol. 2015; 65: 1249-1254
- A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).Eur Heart J. 2014; 35: 2010-2020
- Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.J Am Coll Cardiol. 2012; 60: 705-715
- Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling.J Med Genet. 2005; 42: e59
- Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors.Heart Rhythm. 2012; 9: 57-63
- The value of cardiac genetic testing.Trends Cardiovasc Med. 2014; 24: 217-224
- Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy.Genet Med. 2013; 15: 972-977
- Conveying a probabilistic genetic test result to families with an inherited heart disease.Heart Rhythm. 2014; 11: 1073-1078
- Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.JAMA. 2007; 298: 405-412
- The emerging role of the cardiac genetic counselor.Heart Rhythm. 2011; 8: 1958-1962
Article info
Publication history
Published online: October 25, 2017
Accepted:
October 9,
2017
Received:
October 6,
2017
Footnotes
☆This document has been endorsed by the CSANZ Genetic Council.
☆☆This position statement was reviewed by the Quality Standards Committee and ratified at the CSANZ Board meeting held on Friday, 25 November 2016.
Identification
Copyright
© 2017 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.
